TherapeuticsMD (NASDAQ:TXMD) Shares Down 1.6% – Here’s Why

TherapeuticsMD, Inc. (NASDAQ:TXMD) shares fell 1.6% during mid-day trading on Friday. The company traded as low as $1.80 and last traded at $1.80. Approximately 3,832 shares were traded during trading, a decline of 81% from the average daily volume of 20,304 shares. The stock had previously closed at $1.83.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered TherapeuticsMD from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, TherapeuticsMD has an average rating of “Sell”.

TherapeuticsMD Stock Performance

The firm’s fifty day moving average price is $2.05 and its 200 day moving average price is $2.12. The firm has a market cap of $20.83 million, a P/E ratio of 90.00 and a beta of 0.65.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Tuesday, August 11th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.13. The firm had revenue of $0.87 million for the quarter, compared to the consensus estimate of $19.77 million. TherapeuticsMD had a negative net margin of 6.64% and a negative return on equity of 1.09%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TherapeuticsMD stock. Renaissance Technologies LLC grew its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 51.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 146,200 shares of the company’s stock after buying an additional 49,700 shares during the period. Renaissance Technologies LLC owned 1.26% of TherapeuticsMD worth $295,000 at the end of the most recent quarter. Institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc was a pharmaceutical company focused on developing and commercializing products for women’s health. Its portfolio addressed contraception, menopause-related conditions, pregnancy-related nausea, and nutritional support, with products marketed primarily in the United States.

The company’s principal products included ANNOVERA, a reusable, year-long vaginal contraceptive system; IMVEXXY, vaginal inserts containing estradiol for the treatment of moderate to severe vaginal symptoms associated with menopause; and BIJUVA, an oral hormone therapy combining estradiol and progesterone.